University of Oxford spinoff nets a nine-figure Series B, but it won’t beeline toward the clinic

Published

April 29, 2022

University of Oxford spinoff nets a nine-figure Series B, but it won’t beeline toward the clinic

Four years after completing a Series A, an Oxford spinout has returned to the venture well and garnered interest for how its technology is being applied to drug discovery…

MORERelated News
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...
No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work
OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five...